| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
|
J Clin Oncol
|
2013
|
5.67
|
|
2
|
Dissecting the heterogeneity of triple-negative breast cancer.
|
J Clin Oncol
|
2012
|
2.64
|
|
3
|
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
|
J Natl Cancer Inst
|
2008
|
1.95
|
|
4
|
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.
|
Breast Cancer Res Treat
|
2009
|
1.86
|
|
5
|
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
|
Clin Cancer Res
|
2008
|
1.63
|
|
6
|
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer.
|
Clin Cancer Res
|
2010
|
1.57
|
|
7
|
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients.
|
Cancer
|
2011
|
1.53
|
|
8
|
Multifactorial approach to predicting resistance to anthracyclines.
|
J Clin Oncol
|
2011
|
1.52
|
|
9
|
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.
|
Breast Cancer Res Treat
|
2010
|
1.50
|
|
10
|
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
|
J Natl Cancer Inst
|
2009
|
1.47
|
|
11
|
Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer.
|
Clin Breast Cancer
|
2004
|
1.46
|
|
12
|
Management of triple negative breast cancer.
|
Breast
|
2010
|
1.43
|
|
13
|
Metabolomics: available results, current research projects in breast cancer, and future applications.
|
J Clin Oncol
|
2007
|
1.42
|
|
14
|
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
|
J Clin Oncol
|
2009
|
1.40
|
|
15
|
Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
|
J Clin Oncol
|
2002
|
1.39
|
|
16
|
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
|
Nat Rev Clin Oncol
|
2009
|
1.34
|
|
17
|
Breast cancer assessment tools and optimizing adjuvant therapy.
|
Nat Rev Clin Oncol
|
2010
|
1.32
|
|
18
|
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.
|
Breast Cancer Res
|
2009
|
1.28
|
|
19
|
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.
|
Breast Cancer Res Treat
|
2012
|
1.26
|
|
20
|
Targeting triple negative breast cancer: is p53 the answer?
|
Cancer Treat Rev
|
2013
|
1.23
|
|
21
|
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
|
Mol Cancer Ther
|
2004
|
1.17
|
|
22
|
Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer.
|
J Clin Oncol
|
2003
|
1.13
|
|
23
|
Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice.
|
Clin Cancer Res
|
2005
|
1.13
|
|
24
|
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.
|
Clin Breast Cancer
|
2002
|
1.11
|
|
25
|
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
|
J Clin Oncol
|
2009
|
1.07
|
|
26
|
DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.
|
Oncologist
|
2013
|
1.04
|
|
27
|
Uncovering the metabolomic fingerprint of breast cancer.
|
Int J Biochem Cell Biol
|
2010
|
1.04
|
|
28
|
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.
|
Mol Cancer Ther
|
2006
|
1.03
|
|
29
|
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
|
Clin Cancer Res
|
2008
|
1.02
|
|
30
|
HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact.
|
Cancer Treat Rev
|
2013
|
1.00
|
|
31
|
Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98.
|
Psychooncology
|
2013
|
0.97
|
|
32
|
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.
|
Breast Cancer Res Treat
|
2012
|
0.96
|
|
33
|
Predicting anthracycline benefit: have we made any progress?
|
Curr Opin Oncol
|
2009
|
0.95
|
|
34
|
The nutritional risk in oncology: a study of 1,453 cancer outpatients.
|
Support Care Cancer
|
2012
|
0.95
|
|
35
|
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
|
Eur J Cancer
|
2007
|
0.94
|
|
36
|
Resistance to trastuzumab: a necessary evil or a temporary challenge?
|
Clin Breast Cancer
|
2002
|
0.92
|
|
37
|
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study.
|
Mol Oncol
|
2012
|
0.92
|
|
38
|
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
|
Clin Breast Cancer
|
2008
|
0.89
|
|
39
|
Feasibility of evaluating quality cancer care using registry data and electronic health records: a population-based study.
|
Int J Qual Health Care
|
2012
|
0.88
|
|
40
|
Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy.
|
Curr Opin Oncol
|
2014
|
0.87
|
|
41
|
Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?
|
Ecancermedicalscience
|
2013
|
0.86
|
|
42
|
Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven.
|
J Clin Oncol
|
2012
|
0.86
|
|
43
|
International study on inter-reader variability for circulating tumor cells in breast cancer.
|
Breast Cancer Res
|
2014
|
0.86
|
|
44
|
Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.
|
Cancer Manag Res
|
2010
|
0.85
|
|
45
|
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers.
|
BMC Med
|
2015
|
0.84
|
|
46
|
The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
|
Cancer Treat Rev
|
2009
|
0.83
|
|
47
|
The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.
|
PLoS One
|
2013
|
0.83
|
|
48
|
Chemotherapy for metastatic breast cancer.
|
Curr Opin Obstet Gynecol
|
2004
|
0.82
|
|
49
|
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.
|
Breast Cancer Res Treat
|
2013
|
0.82
|
|
50
|
Extensive deep vein thrombosis as a complication of testicular cancer treated with the BEP protocol (bleomycin, etoposide and cisplatin): case report.
|
Sao Paulo Med J
|
2006
|
0.82
|
|
51
|
Triple negative breast cancer: a heterogeneous subgroup defined by what it is not.
|
Eur J Cancer
|
2011
|
0.82
|
|
52
|
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review.
|
Tumori
|
2012
|
0.81
|
|
53
|
Gastric cancer metastatic to the pituitary gland: a case report.
|
Tumori
|
2007
|
0.81
|
|
54
|
The continued evidence from overviews: what is the clinical utility?
|
Breast
|
2013
|
0.81
|
|
55
|
Adjuvant systemic treatment for individual patients with triple negative breast cancer.
|
Breast
|
2011
|
0.80
|
|
56
|
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.
|
Curr Med Res Opin
|
2010
|
0.79
|
|
57
|
Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream.
|
J Clin Oncol
|
2008
|
0.79
|
|
58
|
Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer.
|
Cancer Treat Rev
|
2002
|
0.79
|
|
59
|
Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more?
|
Breast
|
2009
|
0.78
|
|
60
|
Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancer.
|
Cancers (Basel)
|
2010
|
0.77
|
|
61
|
HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.
|
Anticancer Res
|
2002
|
0.76
|
|
62
|
Taxanes in the elderly: can we gain as much and be less toxic?
|
Crit Rev Oncol Hematol
|
2008
|
0.76
|
|
63
|
Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
|
Future Oncol
|
2011
|
0.76
|
|
64
|
Adjuvant chemotherapy: which patient? What regimen?
|
Am Soc Clin Oncol Educ Book
|
2013
|
0.76
|
|
65
|
Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients.
|
Breast
|
2012
|
0.76
|
|
66
|
TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.
|
Future Oncol
|
2013
|
0.75
|
|
67
|
Re-searching anthracycline therapy.
|
Breast Cancer Res Treat
|
2010
|
0.75
|
|
68
|
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin.
|
J Clin Oncol
|
2002
|
0.75
|
|
69
|
Ode to a past emperor.
|
J Clin Oncol
|
2010
|
0.75
|
|
70
|
[HER2 and topoisomerase II alpha: useful clinical markers in breast cancer].
|
Bull Cancer
|
2008
|
0.75
|
|
71
|
Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?
|
Crit Rev Oncol Hematol
|
2007
|
0.75
|
|
72
|
3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
|
Anticancer Res
|
2002
|
0.75
|
|
73
|
Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients.
|
Radiother Oncol
|
2008
|
0.75
|